• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 289

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation...

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Catching Up With the Psychedelic Entourage Effect: Part 5 – MindMed

The Psychedelic Entourage Effect: Part 6 – The State of the...

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

1...288289290...306Page 289 of 306

EDITOR PICKS

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©